Results 291 to 300 of about 6,410,935 (343)

Endogenous Peptide Inhibitors of HIV Entry

2022
The discovery of the G-protein coupled-receptor (GPCR) CXCR4 as a major coreceptor of HIV-1 entry about three decades ago explained why the chemokine SDF-1/CXCL12 inhibits specific viral strains. The knowledge that RANTES, MlP-1α, and MlP-1β specifically inhibit other primary HIV-1 strains allowed the rapid discovery of CCR5 as second major viral ...
Mirja, Harms, Manuel, Hayn, Fabian, Zech, Frank, Kirchhoff, Jan, Münch   +4 more
openaire   +2 more sources

HIV-1 entry inhibitor entrances

Trends in Pharmacological Sciences, 2004
Abstract BMS-378806 is a newly described small-molecule inhibitor of human immunodeficiency virus type 1 (HIV-1) replication. It acts by binding to the gp120 surface glycoprotein of the virus within, or very close to, the pocket normally occupied by the CD4 antigen, the primary cell-surface receptor protein of HIV-1.
Shawn E, Kuhmann, John P, Moore
openaire   +2 more sources

Resistance to HIV-1 Entry Inhibitors

Current Drug Target -Infectious Disorders, 2003
Resistance-testing technology has been incorporated into the standard of care for human immunodeficiency virus type 1 (HIV-1) infection and therapy with protease and reverse transcriptase inhibitors. Inhibitors of HIV-1 entry represent an emerging mode of antiretroviral therapy, and HIV-1 entry inhibitors encompass three mechanistically distinct ...
W C, Olson, P J, Maddon
openaire   +2 more sources

Entry Inhibitors of Hepatitis C Virus

2022
Hepatitis C virus (HCV) infection affects approximately 1% of the world's population and is a major cause of chronic liver diseases. Although antiviral therapy consisting of direct-acting antivirals (DAAs) can cure the majority of HCV patients, it is still limited by viral resistances, drug-drug interactions, and high costs.
Xi-Jing, Qian, Zhong-Tian, Qi
openaire   +2 more sources

Nonpeptide Inhibitors of Measles Virus Entry

Journal of Medicinal Chemistry, 2006
Measles virus (MV) is one of the most infectious pathogens known. Despite the existence of a vaccine, over 500,000 deaths/year result from MV or associated complications. Anti-measles compounds could conceivably reverse these statistics. Previously, we described a homology model of the MV fusion protein trimer and a putative binding site near the head ...
Aiming, Sun, Andrew, Prussia, Weiqiang, Zhan, Ernest E, Murray, Joshua, Doyle, Li-Ting, Cheng, Jeong-Joong, Yoon, Eugene V, Radchenko, Vladimir A, Palyulin, Richard W, Compans, Dennis C, Liotta, Richard K, Plemper, James P, Snyder   +12 more
openaire   +2 more sources

Zika virus entry inhibitors

Bioorganic & Medicinal Chemistry
Viral entry step involves of complex host-virus interactions. Research progress of viral entry inhibitors lags significantly behind that of viral replication inhibitors targeting viral non-structural proteins. Here we take Zika virus (ZIKV), a neglected flavivirus currently lacking effective therapeutic drugs, as an example of enveloped RNA viruses to ...
Weiyi, Yin, Rui, Zhou, Wencui, Zhang, Yanping, Li   +3 more
openaire   +2 more sources

HIV entry inhibitors in clinical development

Current Opinion in Pharmacology, 2002
Despite recent advances, present therapies for human immunodeficiency virus type 1 (HIV-1) infection are limited by their failure to eradicate HIV-1, by the emergence of multidrug-resistant variants and by significant toxicities. Current therapies collectively target two viral enzymes involved in intracellular viral replication processes, and there is ...
Bryan M, O'Hara, William C, Olson
openaire   +2 more sources

Human Papillomavirus (HPV) Entry Inhibitors

2022
Chronic or persistent human papillomavirus (HPV) infection is essential for the development of many types of carcinomas, such as cervical carcinoma. Developing new diagnostic and prognostic biomarkers and designing more effective targeted therapeutics and treatment strategies remains urgent.
openaire   +2 more sources

An Insight on the Leading HIV Entry Inhibitors

Recent Patents on Anti-Infective Drug Discovery, 2006
The main strategies nowadays to fight AIDS rely on chemical therapy to inhibit the reverse transcriptase or protease of HIV. However, a synthetic 36 amino-acids peptide that blocks the entry of the virus in the target cells (enfuvirtide) has recently reached approval for clinical application.
Ana Salomé, Veiga, Nuno C, Santos, Miguel A R B, Castanho   +2 more
openaire   +2 more sources

HIV-Resistance to Viral Entry Inhibitors

Current Pharmaceutical Design, 2004
An increasing number of human immunodeficiency virus (HIV)-infected patients have detectable viraemia despite treatment with multiple-drug combinations or have developed resistance to all available classes of antiretroviral therapy. HIV entry has become an important pharmacological target. Enfuvirtide is the first HIV entry inhibitor to be approved for
Luis, Menéndez-Arias, José A, Esté
openaire   +2 more sources